8-K current report · filed Aug 6, 2026

Sionna Therapeutics, Inc. (SION) 8-K Current Report: August 6, 2026

Item 2.02Item EX-99.1SION overview

Short answer

Sionna Therapeutics, Inc. (SION) filed an 8-K current report with the SEC on August 6, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Press release covers Sionna Therapeutics’ quarter ended June 30, 2026.

Sionna Therapeutics, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Press release covers Sionna Therapeutics’ quarter ended June 30, 2026
  • Financial results and business highlights available in Exhibit 99.1
  • Investor focus: quarterly cash position, clinical progress and development outlook in the attached release

Item EX-99.1 · Exhibit EX-99.1

  • Q2 2026 net loss $29.9M, widening from $18.1M; loss per share $0.66 versus $0.41
  • R&D spending $21.9M, up from $15.4M, reflecting accelerated clinical pipeline investment
  • Cash, equivalents and marketable securities $268.3M, expected to fund operations into 2028
  • Topline data expected summer 2026 for SION-719 Phase 2a and SION-451 Phase 1 combination trials
  • Six-month net loss $56.7M versus $34.6M, signaling rising cash consumption despite extended runway

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Sionna Therapeutics, Inc. 8-K filings

Get the next SION 8-K as it lands

Follow SION for push alerts, or ask the research agent what this filing means.